Biotech Values

[urche]

Merrimack/GTCB

Thanks for the Merrimack news, Dew.
I think this round of private financing is probably indirect good news for GTCB.

Proceeds from the funding will be used to advance Merrimack's proprietary pipeline of biologic therapies targeting autoimmune disease and cancer. The Company's lead product, MM-093, is a novel treatment for autoimmune disease, including rheumatoid arthritis, psoriasis and multiple sclerosis. MM-093 is currently in a Phase 2b dose ranging study in rheumatoid arthritis and a phase 2a pilot study in psoriasis. Results from the two studies are expected later this year.

One would assume these investors have been informed of the results of MM-093 studies in RA that were completed I think last fall. Being a private company has advantages in that material events such as this need not be disclosed to competitors. It doesn't seem to be a stretch to assume GTCB is going to be asked to supply more alphafetoprotein.

urche